SWOG Cancer Research Network
@swog.org
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956. Member NCTN & NCORP. Online at swog.org. @SupportingSWOG.bsky.social partner.
From our @swog.org group chair's Front Line blog:
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
November 7, 2025 at 7:33 PM
From our @swog.org group chair's Front Line blog:
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
WNT signaling in cancer: molecular mechanisms and potential therapies - Molecular Biomedicine
The WNT signaling pathway, a fundamental molecular network regulating cell proliferation, differentiation, and stemness, plays a critical role in tumorigenesis, cancer progression, and therapeutic res...
doi.org
November 7, 2025 at 5:01 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S.
lung-map.org
@focr.bsky.social @swog.org
lung-map.org
@focr.bsky.social @swog.org
November 6, 2025 at 5:02 PM
Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S.
lung-map.org
@focr.bsky.social @swog.org
lung-map.org
@focr.bsky.social @swog.org
Our @swog.org group chair's Front Line blog:
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
November 4, 2025 at 12:53 PM
Our @swog.org group chair's Front Line blog:
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
October 31, 2025 at 4:21 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Our @swog.org group chair's Front Line blog:
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
October 27, 2025 at 3:46 PM
Our @swog.org group chair's Front Line blog:
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions - Molecular Cancer
Cancer cells express high levels of programmed cell death-ligand 1 (PD-L1) to evade immune surveillance. PD-L1 interacts with PD-1 on T cells to make them non-functional. Thus, PD-L1 and PD-1 are pivo...
doi.org
October 27, 2025 at 3:35 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Latest results from @swog.org DART rare cancers trial, out in J for ImmunoTherapy of Cancer:
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors ...
Background Malignant perivascular epithelioid cell tumors (PEComas) are ultra-rare, aggressive mesenchymal neoplasms associated with poor outcomes. Standard-of-care systemic therapy includes mammalian...
jitc.bmj.com
October 22, 2025 at 12:58 PM
Latest results from @swog.org DART rare cancers trial, out in J for ImmunoTherapy of Cancer:
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Reposted by SWOG Cancer Research Network
From the @swog.org Front Line:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan | SWOG
Today, I’m excited to discuss our next myeloma committee chair, Dr. Amrita Y. Krishnan, who will formally step into the role on November 1st (I briefly welcomed her at plenary in Chicago – this is my ...
www.swog.org
October 20, 2025 at 4:34 PM
From the @swog.org Front Line:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
October 17, 2025 at 8:35 PM
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
Our @swog.org group chair's blog:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
October 17, 2025 at 3:52 PM
Our @swog.org group chair's blog:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
October 17, 2025 at 3:50 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Reposted by SWOG Cancer Research Network
Team Hope returns to Arizona in March!
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
October 16, 2025 at 3:05 PM
Team Hope returns to Arizona in March!
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
Finance and work changes among caregivers of patients with metastatic colorectal cancer (mCRC): Secondary analysis of @swog.org S1417CD. from #ASCOQLTY25
in JCO Oncology Practice
ascopubs.org/doi/abs/10.1...
in JCO Oncology Practice
ascopubs.org/doi/abs/10.1...
Finance and work changes among caregivers of patients with metastatic colorectal cancer (mCRC): Secondary analysis of SWOG S1417CD. | JCO Oncology Practice
297Background: We previously found that nearly 75% of mCRC patients enrolled in a multicenter, longitudinal,
prospective cohort study (S1417CD) reported major financial hardship following diagnosis.
H...
ascopubs.org
October 15, 2025 at 4:38 PM
Finance and work changes among caregivers of patients with metastatic colorectal cancer (mCRC): Secondary analysis of @swog.org S1417CD. from #ASCOQLTY25
in JCO Oncology Practice
ascopubs.org/doi/abs/10.1...
in JCO Oncology Practice
ascopubs.org/doi/abs/10.1...
Reposted by SWOG Cancer Research Network
Application open now:
All #SWOGonc CRAs and nurses, submit a request to travel to the spring 2026 @swog.org group meeting - due January 15
thehopefoundation.org/funding-oppo...
All #SWOGonc CRAs and nurses, submit a request to travel to the spring 2026 @swog.org group meeting - due January 15
thehopefoundation.org/funding-oppo...
October 13, 2025 at 2:21 PM
Application open now:
All #SWOGonc CRAs and nurses, submit a request to travel to the spring 2026 @swog.org group meeting - due January 15
thehopefoundation.org/funding-oppo...
All #SWOGonc CRAs and nurses, submit a request to travel to the spring 2026 @swog.org group meeting - due January 15
thehopefoundation.org/funding-oppo...
Reposted by SWOG Cancer Research Network
The @swog.org Front Line:
Pharmaceutical Sciences: A Unique SWOG Legacy #SWOGonc
www.swog.org/news-events/...
Pharmaceutical Sciences: A Unique SWOG Legacy #SWOGonc
www.swog.org/news-events/...
Pharmaceutical Sciences: A Unique SWOG Legacy | SWOG
Her three-decade tenure as our go-to expert on pharmaceutical sciences issues makes her, I believe, the longest-serving committee chair in SWOG history (disclaimer: membership records from our first t...
www.swog.org
October 7, 2025 at 2:11 PM
The @swog.org Front Line:
Pharmaceutical Sciences: A Unique SWOG Legacy #SWOGonc
www.swog.org/news-events/...
Pharmaceutical Sciences: A Unique SWOG Legacy #SWOGonc
www.swog.org/news-events/...
Reposted by SWOG Cancer Research Network
Breast pain doesn't always mean cancer but symptoms that don't go away within reasonable time or with home care need evaluation by your HCP. Take it seriously & keep pushing for answers. www.ibcresearch.org
October 9, 2025 at 2:34 AM
Breast pain doesn't always mean cancer but symptoms that don't go away within reasonable time or with home care need evaluation by your HCP. Take it seriously & keep pushing for answers. www.ibcresearch.org
Reposted by SWOG Cancer Research Network
Thanks to all who made our Chicago group meeting a success! It went by too quickly, but it’s always refreshing to see our #SWOGonc community in person. We're grateful for our donors 🙏 And for those who picked up some new @swog.org swag, we’re excited to see where you’ll be spotted wearing it!
September 24, 2025 at 5:07 PM
Our fall 2025 @swog.org group meeting was a memorable one! Recordings of hybrid sessions (ie, most open sessions) will be available to SWOG members soon, behind password on swog.org. Watch the website! www.swog.org/swog-fall-20... #SWOGonc @supportingswog.bsky.social
September 22, 2025 at 5:24 PM
Our fall 2025 @swog.org group meeting was a memorable one! Recordings of hybrid sessions (ie, most open sessions) will be available to SWOG members soon, behind password on swog.org. Watch the website! www.swog.org/swog-fall-20... #SWOGonc @supportingswog.bsky.social
There's no doubt about it, @lauraesfeller.bsky.social -- you're making all of @swog.org proud! Thank you!!
I wouldn’t be alive today if he wouldn’t have been my onc. He gave me hope when I needed it most & treated me as a human 1st, patient 2nd. My only regret is not being able to work w/him @swog.org Hope I’m making you proud, Dr. V. I owe you everything! #VogelzangScholars @supportingswog.bsky.social
September 21, 2025 at 3:03 PM
There's no doubt about it, @lauraesfeller.bsky.social -- you're making all of @swog.org proud! Thank you!!
Reposted by SWOG Cancer Research Network
Strong showing from #GUonc #patientadvocates @swog.org: Darrell Nakagawa at #S2427 BRIGHT & Joël Pointon at #CCTG-PR.26 kickoff mtgs. Exciting to see new #bladdercancer & #prostatecancer trials open! THANK YOU to SWOG GU Cmte & @supportingswog.bsky.social for including & elevating patient voices!
September 20, 2025 at 3:37 PM
Strong showing from #GUonc #patientadvocates @swog.org: Darrell Nakagawa at #S2427 BRIGHT & Joël Pointon at #CCTG-PR.26 kickoff mtgs. Exciting to see new #bladdercancer & #prostatecancer trials open! THANK YOU to SWOG GU Cmte & @supportingswog.bsky.social for including & elevating patient voices!
Reposted by SWOG Cancer Research Network
@swog.org #S2200 is also still accruing!! An important trial since there are so few for #papillaryRCC. Also happy to chat w/ patients considering this for metastatic #papillarykidneycancer. In this limited non-clear cell space, patients deserve more trials like this! #SWOGFall2025
September 20, 2025 at 3:19 PM
@swog.org #S2200 is also still accruing!! An important trial since there are so few for #papillaryRCC. Also happy to chat w/ patients considering this for metastatic #papillarykidneycancer. In this limited non-clear cell space, patients deserve more trials like this! #SWOGFall2025
The @swog.org Latin America Initiative Symposium at the fall group meeting is discussing collaboration on breast cancer research. In updates from member sites, Dr. Tatiana Vidaurre, of Peru's INEN, reports on a project using AI to assist w breast cancer diagnoses.
September 20, 2025 at 3:14 PM
The @swog.org Latin America Initiative Symposium at the fall group meeting is discussing collaboration on breast cancer research. In updates from member sites, Dr. Tatiana Vidaurre, of Peru's INEN, reports on a project using AI to assist w breast cancer diagnoses.
Reposted by SWOG Cancer Research Network
@swog.org #S1931 PROBE is still open & accruing! This will answer a crucial question in our #kidneycancer community: does #nephrectomy improve outcomes when combined w/ immunotherapy? #metastaticRCC #SWOGFall25 Happy to chat with patients considering this trial anytime.
September 20, 2025 at 3:08 PM
@swog.org #S1931 PROBE is still open & accruing! This will answer a crucial question in our #kidneycancer community: does #nephrectomy improve outcomes when combined w/ immunotherapy? #metastaticRCC #SWOGFall25 Happy to chat with patients considering this trial anytime.
KICKOFF session for S2427 BRIGHT trial,
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
September 18, 2025 at 7:20 PM
KICKOFF session for S2427 BRIGHT trial,
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...